News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vivo Ventures Leads $30 Million Funding of Shanghai Jingfeng Pharma


11/6/2012 6:24:40 AM

by Richard Daverman, PhD

November 5, 2012 -- Vivo Ventures, the California-China healthcare venture capital company, is the lead investor in a 190 million RMB ($30 million) funding round for Shanghai Jingfeng Pharmaceutical Co., according to Venture Wire. In January, Vivo closed Vivo Ventures VII, a $375 million fund. It pledged to allocate 45% of that to China life science companies. Founded in 2003, Shanghai Jingfeng Pharma is GMP-certified by the SFDA to make sodium hyaluronate API. More details....


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES